Profotenofovir (TAF) versus Entecavir (ETV) in prevention of Hepatitis B associated liver cancer recurrence after hepatectomy: a prospective, randomized controlled study

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200063159

Enrollment

Unknown

Registered

2022-09-01

Start date

2022-09-01

Completion date

Unknown

Last updated

2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatocellular carcinoma

Interventions

TAF group:Tenofovir

ETV group:Entecavir

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. No gender limit, patients aged 18-75 years; 2. Hepatocellular carcinoma was clinically diagnosed or histopathologically combined with HBsAg(+); 3. Patients with BCLC 0-A hepatocellular carcinoma undergoing hepatectomy; 4. ECOG score 0-1, Child-Pugh grade A; 5. Did not receive anti-tumor therapy or other anti-hepatitis B drugs before surgery; 6. Sign written informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with hepatitis C; 2. Patients with HIV infection; 3. Patients with extrahepatic metastasis; 4. Ascites, hepatic encephalopathy, Gilbert syndrome, sclerosing cholangitis, etc.; 5. The investigator considered it inappropriate to participate in the clinical trial.

Design outcomes

Primary

Measure	Time frame
Recurrence-free survival;	—

Secondary

Measure	Time frame
Adverse events;	—

Countries

China

Contacts

Public ContactWen Tianfu

West China Hospital of Sichuan University

wentianfu@scu.edu.cn+86 18980601471

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026